LTR PHARMA LIMITED

2.08%

49.0¢

Market Cap $87.18M

Healthcare Biotechnology

LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The... LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is developing and commercializing therapies that address significant unmet medical needs. The Company is focused on improving men’s health through clinical development and commercialization of nasal spray treatments for erectile dysfunction. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. The Company is also advancing OROFLOW, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) - a debilitating group of conditions affecting swallowing function. The Company's subsidiary is LTR Pharma Inc.More

Neurizon's (ASX:NUZ) NUZ-001 OLE Study Demonstrates Long-Term Safety and Efficacy Signals

Latest Threads

Tag

Subject

LTP

Ann: SPONTAN Shows Positive Outcomes in Younger Men with ED

09/02/26

5.6K

09/02/26

Last post demons12

5.6K

LTP

Ann: Quarterly Activities/Appendix 4C Cash Flow Report

31/01/26

5.7K

31/01/26

Last post VMVarga

5.7K

LTP

Up we Go

29/01/26

3.5K

29/01/26

Last post Trostc1

3.5K

LTP

Its about to Blow

28/01/26

262

28/01/26

Last post conroy

262

LTP

Ann: First Patients Dosed in SPONTAN Phase II Clinical Study

23/01/26

3.9K

23/01/26

Last post Bagger28

3.9K

LTP

Ann: Application for quotation of securities - LTP

21/01/26

314

21/01/26

Last post

ASX News

314

LTP

Ann: Patient Recruitment Commences for SPONTAN Phase II Study

21/01/26

2.4K

21/01/26

Last post smoker101

2.4K

LTP

Ann: LTR Pharma Surpasses 1,000 SPONTAN Prescriptions

2 3 4

20/01/26

215

28K

20/01/26

Last post VMVarga

215

28K

See All Discussions

Timeline

SPONTAN Shows Positive Outcomes in Younger Men with ED
02 Feb 08:46	Share

Quarterly Activities/Appendix 4C Cash Flow Report
28 Jan 08:27	Share

First Patients Dosed in SPONTAN Phase II Clinical Study
22 Jan 08:52	Share

Application for quotation of securities - LTP
21 Jan 15:35	Share

Notification regarding unquoted securities - LTP
16 Jan 16:58	Share

Patient Recruitment Commences for SPONTAN Phase II Study
13 Jan 08:23	Share

SPONTAN Phase 1 Study Accepted for WMSM 2026 Podium
08 Jan 09:14	Share

Notification regarding unquoted securities - LTP
22 Dec 17:03	Share

LTR Pharma Surpasses 1,000 SPONTAN Prescriptions
17 Dec 09:12	Share

Application for quotation of securities - LTP
11 Dec 09:45	Share

TGA Provides Regulatory Clearance for SPONTAN Phase II
10 Dec 09:38	Share

Ethics Approval Received for SPONTAN Phase II Clinical Study
03 Dec 09:19	Share

Release of Restricted Securities from ASX Mandatory Escrow
02 Dec 15:12	Share

Change of Director's Interest Notice - M McGuire
20 Nov 15:43	Share

Change of Director's Interest Notice - J Chick
20 Nov 15:40	Share

Change of Director's Interest Notice - L Rodne
20 Nov 15:38	Share

Notification regarding unquoted securities - LTP
20 Nov 10:13	Share

Notification regarding unquoted securities - LTP
20 Nov 10:06	Share

Application for quotation of securities - LTP
20 Nov 09:59	Share

Bell Potter Healthcare conference presentation
19 Nov 08:32	Share

Investor Presentation
30 Oct 09:43	Share

Quarterly Activities/Appendix 4C Cash Flow Report
29 Oct 08:51	Share

Results of Meeting
24 Oct 16:32	Share

AGM Presentation
24 Oct 14:35	Share

LTR increases LevOmega stake to 43% with $1m investment
06 Oct 08:37	Share

Application for quotation of securities - LTP
26 Sep 09:56	Share

Notice of Annual General Meeting/Proxy Form
23 Sep 13:56	Share

LTR Pharma secures 33% ownership in LevOmega Pty Ltd
22 Sep 08:27	Share

FY25 Results Announcement
29 Aug 08:49	Share

Appendix 4G and Corporate Governance Statement
29 Aug 08:49	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 49.0¢		Change 0.010(2.08%)		Mkt cap ! $87.18M

Open	High	Low	Volume
48.5¢	51.0¢	48.5¢	109.6K

Buyers (Bids)

Vol.	Price($)
10638	48.0¢

Sellers (Offers)

Price($)	Vol.
50.5¢	5000

Last trade - 16.17pm 09/02/2026 (20 minute delay)

LTP (ASX) Chart

LTR PHARMA LIMITED

Latest Threads

Advance Metals Uncovers New High-Grade Silver-Gold Zones at Yoquivo

Timeline

Featured News

Latest Articles

Investors surprised as LTR Pharma, an erectile dysfunction biotech, moves into... omega-3 fish oil

LTR Pharma has made an interesting move – the erectile dysfunction nasal spray company is moving into the Omega 3 fish oil game.

LTR Pharma dips -6% as US growth plans confuse with two identical products to be launched

LTR Pharma has revealed its latest plan to further expand into the U.S. – with a product, Roxus, it says taps into "personalised healthcare."

LTR Pharma pairs with Men's Health Downunder for supply of erectile dysfunction spray

LTR Pharma Ltd has signed an agreement with Men's Health Downunder to facilitate supply of its lead nasal spray SPONTAN

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News